BIIB
July 31, 2025 - AI Summary
Undervalued by 126.6% based on the discounted cash flow analysis.
Market cap | $23.44 Billion |
---|---|
Enterprise Value | $27.91 Billion |
Dividend Yield | $- (-) |
Earnings per Share | $11.2 |
Beta | 0.13 |
Outstanding Shares | 145,900,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 15.24 |
---|---|
PEG | 173.72 |
Price to Sales | 2.35 |
Price to Book Ratio | 1.33 |
Enterprise Value to Revenue | 2.79 |
Enterprise Value to EBIT | 61.89 |
Enterprise Value to Net Income | 18 |
Total Debt to Enterprise | 0.26 |
Debt to Equity | 0.41 |
No data
No data
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...